About: http://data.cimple.eu/news-article/b56357962ebcffd6a3a9a0dd589f797b4ffdcd22a4554ea483bd04be

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/b56357962ebcffd6a3a9a0dd589f797b4ffdcd22a4554ea483bd04be Goto Sponge Distinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	Brexit has helped Britain accelerate the landmark rollout of a Covid-19 vaccine while the European Union lags on its own approval, Health Secretary Matt Hancock said on Wednesday. But the UK's Medicines and Healthcare products Regulatory Agency (MHRA), after giving its green light to introduce the Pfizer-BioNTech vaccine, gave a more nuanced view. "Whilst until earlier this year we were in the European Medicines Agency (EMA), because of Brexit we've been able to make a decision to do this based on the UK regulator, a world-class regulator," Hancock told Times radio. As a result, Britain was able to "not go at the pace of the Europeans, who are moving a little bit more slowly," he said. Britain formally quit the EU in January, and the EMA has relocated from London to Amsterdam. But the country remains in a post-Brexit transition period until the end of this year, and EU pharmaceutical regulations still apply for now. "We have been able to announce the supply of this vaccine using provisions under EU law which exists until January 1," MHRA chief executive June Raine told a news conference. "Our speed and our provision has been totally dependent on the available data in our rolling review," she stressed, insisting the agency had taken no shortcuts in approving the vaccine. The EMA on Tuesday said it would hold an extraordinary meeting on December 29 "at the latest" to consider its own emergency approval for the vaccine developed by Germany's BioNTech and US giant Pfizer. Another US company, Moderna, said it was filing Monday for emergency authorisation of its vaccine in the United States and Europe. Britain and the EU are meanwhile locked in tense negotiations to craft a new trading partnership from January 1. Failure to strike a deal will seriously disrupt cross-Channel trade, although Hancock says planes are on standby to replace ships for ferrying supplies of the Pfizer-BioNTech vaccine to Britain from its manufacturing base in Belgium. jit/phz/gd
schema:headline	Brexit helped UK accelerate Covid vaccine approval: govt
schema:mentions	Secretary of State for Health and Social Care European Single Market Medicines and Healthcare products Regulatory Agency Matt Hancock European Medicines Agency Hertz Pharmaceutical industry Belgium Radio Brexit Germany London European Union Pfizer Coronavirus disease United Kingdom Vaccine United States Coronavirus disease 2019 Hancock's Half Hour Euronext
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2020-12-02 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	positive sentiment
http://data.cimple...readability_score	85 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 11 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software